Q1 Earnings Estimate for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a report released on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($1.20) EPS.

NAMS has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $25.46 on Friday. NewAmsterdam Pharma has a 52-week low of $10.29 and a 52-week high of $27.29. The stock’s 50-day simple moving average is $21.16 and its 200 day simple moving average is $18.90.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise bought a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at about $38,000. Quarry LP lifted its holdings in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after buying an additional 6,247 shares during the period. Barclays PLC boosted its position in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $187,000. 89.89% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares of the company’s stock, valued at $283,110,204.79. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 252,814 shares of company stock valued at $5,970,327 in the last quarter. Insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.